375 related articles for article (PubMed ID: 16752077)
1. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases.
Leuschner C; Kumar CS; Hansel W; Soboyejo W; Zhou J; Hormes J
Breast Cancer Res Treat; 2006 Sep; 99(2):163-76. PubMed ID: 16752077
[TBL] [Abstract][Full Text] [Related]
2. Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastases.
Zhou J; Leuschner C; Kumar C; Hormes JF; Soboyejo WO
Biomaterials; 2006 Mar; 27(9):2001-8. PubMed ID: 16280161
[TBL] [Abstract][Full Text] [Related]
3. Application of luteinizing hormone-releasing hormone-ferrosoferric oxide nanoparticles in targeted imaging of breast tumors.
Nian D; Shi P; Sun J; Ren L; Hao X; Han J
J Int Med Res; 2019 Apr; 47(4):1749-1757. PubMed ID: 30880516
[TBL] [Abstract][Full Text] [Related]
4. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo.
Hansel W; Enright F; Leuschner C
Mol Cell Endocrinol; 2007 Jan; 260-262():183-9. PubMed ID: 17101210
[TBL] [Abstract][Full Text] [Related]
5. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo.
Leuschner C; Enright FM; Gawronska B; Hansel W
Breast Cancer Res Treat; 2003 Mar; 78(1):17-27. PubMed ID: 12611453
[TBL] [Abstract][Full Text] [Related]
6. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases.
Hansel W; Leuschner C; Enright F
Mol Cell Endocrinol; 2007 Apr; 269(1-2):26-33. PubMed ID: 17382461
[TBL] [Abstract][Full Text] [Related]
7. Glutaric acid as a spacer facilitates improved intracellular uptake of LHRH-SPION into human breast cancer cells.
Kumar CS; Leuschner C; Urbina M; Ozkaya T; Hormes J
Int J Nanomedicine; 2007; 2(2):175-9. PubMed ID: 17722545
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice.
Kato Y; Zhu W; Backer MV; Neoh CC; Hapuarachchige S; Sarkar SK; Backer JM; Artemov D
Pharm Res; 2015 Nov; 32(11):3746-3755. PubMed ID: 26078000
[TBL] [Abstract][Full Text] [Related]
10. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
11. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors.
Leuschner C; Enright FM; Gawronska-Kozak B; Hansel W
Prostate; 2003 Sep; 56(4):239-49. PubMed ID: 12858351
[TBL] [Abstract][Full Text] [Related]
12. Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo.
Xie H; Zhu Y; Jiang W; Zhou Q; Yang H; Gu N; Zhang Y; Xu H; Xu H; Yang X
Biomaterials; 2011 Jan; 32(2):495-502. PubMed ID: 20970851
[TBL] [Abstract][Full Text] [Related]
13. Pt-Mal-LHRH, a Newly Synthesized Compound Attenuating Breast Cancer Tumor Growth and Metastasis by Targeting Overexpression of the LHRH Receptor.
Calderon LE; Keeling JK; Rollins J; Black CA; Collins K; Arnold N; Vance DE; Ndinguri MW
Bioconjug Chem; 2017 Feb; 28(2):461-470. PubMed ID: 27997127
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of Bombesin-superparamagnetic iron oxide nanoparticles as a targeted contrast agent for imaging of breast cancer using MRI.
Jafari A; Salouti M; Shayesteh SF; Heidari Z; Rajabi AB; Boustani K; Nahardani A
Nanotechnology; 2015 Feb; 26(7):075101. PubMed ID: 25642737
[TBL] [Abstract][Full Text] [Related]
15. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
Schubert A; Hawighorst T; Emons G; Gründker C
Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
17. Luteinizing hormone-releasing hormone targeted superparamagnetic gold nanoshells for a combination therapy of hyperthermia and controlled drug delivery.
Mohammad F; Al-Lohedan HA
Mater Sci Eng C Mater Biol Appl; 2017 Jul; 76():692-700. PubMed ID: 28482580
[TBL] [Abstract][Full Text] [Related]
18. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice.
Jenkins DE; Hornig YS; Oei Y; Dusich J; Purchio T
Breast Cancer Res; 2005; 7(4):R444-54. PubMed ID: 15987449
[TBL] [Abstract][Full Text] [Related]
19. Quantitative [Fe]MRI determination of the dynamics of PSMA-targeted SPIONs discriminates among prostate tumor xenografts based on their PSMA expression.
Sillerud LO
J Magn Reson Imaging; 2018 Aug; 48(2):469-481. PubMed ID: 29331081
[TBL] [Abstract][Full Text] [Related]
20. 99mTc-labeled superparamagnetic iron oxide nanoparticles for multimodality SPECT/MRI of sentinel lymph nodes.
Madru R; Kjellman P; Olsson F; Wingårdh K; Ingvar C; Ståhlberg F; Olsrud J; Lätt J; Fredriksson S; Knutsson L; Strand SE
J Nucl Med; 2012 Mar; 53(3):459-63. PubMed ID: 22323777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
